Recent Advances in Small Cell Lung Cancer (SCLC) Over the Last Decade

Call us

+34 961 487 668

Contact Us

Pioneering research conducted by Melisa Huñis MD and Adrián Huñis MD that integrates the latest advances in small cell lung cancer (SCLC): new immunotherapy treatments, molecular subtypes, imaging diagnostics, and future perspectives.

Melisa Huñis MD

School of Medicine
Universidad de Buenos Aires (Argentina)

Adrián Huñis MD

School of Medicine
Universidad de Buenos Aires (Argentina)

A) Introduction

Small cell lung cancer (SCLC) has long been recognized as a distinct and highly malignant subtype of lung cancer. It is characterized by rapid growth, early dissemination, and a high initial response to chemotherapy and radiotherapy, but also by a propensity for early relapse and resistance to treatment.

For decades, the therapeutic approach to SCLC remained largely unchanged, with platinum-based chemotherapy as the cornerstone of management. However, the last decade has witnessed a renaissance in SCLC research, driven by advances in molecular profiling, the identification of novel therapeutic targets, and the successful incorporation of immunotherapy into first-line treatment. This article aims to provide a comprehensive, up-to-date review of these advances, contextualizing them within the broader clinical management of SCLC.

B) Frequency and Its Relationship with Smoking

SCLC accounts for approximately 13–15% of all lung cancers worldwide, though this proportion has been steadily declining in many developed countries. This trend mirrors the reduction in smoking rates, underscoring the strong etiological link between tobacco exposure and SCLC. Over 95% of SCLC cases occur in current or former smokers, making it one of the malignancies most closely tied to tobacco use. The carcinogens in cigarette smoke induce characteristic genetic alterations, notably in the TP53 and RB1 tumor suppressor genes, which are almost universally inactivated in SCLC. (Fig. 1)

Fig1: Overall survival of never-smokers and smokers with small-cell lung cancer. Never-smokers had better overall survival than smokers (median 18.2 versus 13.1 months, P = 0.054).

THORACIC TUMORSVolume 26, Issue 1P161-166, January 2015

Epidemiologically, the incidence of SCLC varies by region and gender. Historically, SCLC was more common in men, but the gender gap has narrowed in recent decades as smoking patterns have changed. In high-income countries, the incidence of SCLC has decreased, but it remains a significant health burden, particularly in lower- and middle-income nations where tobacco control measures may be less effective.

Table 1. Incidence of SCLC by Region and Year

This strong association with smoking also has implications for prevention and early detection. While low-dose CT screening has shown benefits in NSCLC, its impact on SCLC detection remains limited, as SCLC tends to grow and spread rapidly between screening intervals.

C) Pathology, Molecular Oncology, and Genetics of SCLC

SCLC is a high-grade neuroendocrine carcinoma, characterized histologically by small, round, blue cells with scant cytoplasm, finely granular chromatin, and a high mitotic rate. Immunohistochemical staining is essential for diagnosis, with markers such as synaptophysin, chromogranin A, and CD56 typically positive. The neuroendocrine nature of SCLC also explains its propensity for paraneoplastic syndromes.

The last decade has brought a revolution in our understanding of SCLC biology. Comprehensive genomic profiling has revealed that nearly all SCLCs harbor inactivating mutations in TP53 and RB1, distinguishing them from NSCLC. Beyond these universal alterations, SCLC is now recognized as a heterogeneous disease at the molecular level. Recent research has identified four major molecular subtypes, defined by the expression of key transcription factors: ASCL1, NEUROD1, POU2F3, and YAP1. These subtypes differ in their biology, clinical behavior, and potential therapeutic vulnerabilities.

Fig.2: SCLC Molecular Subtypes and Potential Therapeutic Targets

Fig.2: Pathol. Oncol. Res., 21 April 2024. Volume 30 - 2024

https://doi.org/10.3389/pore.2024.1611743

This molecular heterogeneity has important implications for future drug development. For example, ASCL1- and NEUROD1-driven tumors are more neuroendocrine and may be more sensitive to certain targeted agents, while POU2F3 and YAP1 subtypes show distinct biology and may respond differently to immunotherapy or novel agents. The integration of molecular subtyping into clinical practice is still evolving, but it represents a promising avenue for personalized medicine in SCLC.

D) Clinical Presentation

Clinically, SCLC is notorious for its aggressive course. Most patients present with symptoms related to a central thoracic mass, such as cough, dyspnea, chest pain, or hemoptysis. Because SCLC grows rapidly and metastasizes early, many patients also present with systemic symptoms—weight loss, fatigue, bone pain, or neurological symptoms due to brain metastases or paraneoplastic syndromes.

At diagnosis, approximately two-thirds of patients have extensive-stage disease, defined by the presence of distant metastases. The remaining third have limited-stage disease, confined to one hemithorax and regional lymph nodes, which is potentially curable with aggressive multimodality therapy.

The rapid progression of SCLC means that delays in diagnosis or treatment can have serious consequences. Early recognition of symptoms and prompt initiation of therapy are critical to optimizing outcomes.

E) Paraneoplastic Syndromes

One of the hallmarks of SCLC is its association with paraneoplastic syndromes, which result from ectopic hormone production by tumor cells or from immune-mediated mechanisms. These syndromes can precede, accompany, or follow the diagnosis of cancer, and they may significantly impact morbidity and management.

The most common paraneoplastic syndromes in SCLC include:

• Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Occurs in 10–15% of patients, leading to hyponatremia, confusion, and seizures.
• Cushing’s Syndrome: Due to ectopic ACTH production, seen in 1–5% of patients, causing hypercortisolism, muscle weakness, and metabolic disturbances.
• Lambert-Eaton Myasthenic Syndrome (LEMS): An autoimmune disorder affecting the neuromuscular junction, resulting in proximal muscle weakness and autonomic dysfunction.

Table 2. Common Paraneoplastic Syndromes in SCLC

Management of these syndromes requires a multidisciplinary approach. Treating the underlying cancer often leads to resolution of paraneoplastic symptoms, but supportive care and specific interventions (e.g., fluid restriction for SIADH, immunosuppression for LEMS) are frequently necessary.

F) Tumor Markers in SCLC

Tumor markers have long been explored as potential tools for the diagnosis, prognosis, and monitoring of small cell lung cancer (SCLC). However, unlike some other malignancies, there are currently no tumor markers with sufficient sensitivity or specificity to serve as standalone diagnostic tests for SCLC. Nevertheless, several markers are frequently elevated and can provide adjunctive information in clinical practice.

The most commonly studied serum tumor markers in SCLC include:

• Neuron-Specific Enolase (NSE): Elevated in up to 70–80% of SCLC patients at diagnosis. High levels correlate with tumor burden and may have prognostic value, as persistently elevated or rising NSE during treatment is associated with poor response and shorter survival. However, NSE lacks specificity, as it can also be elevated in other neuroendocrine tumors and some benign conditions.
• Pro-Gastrin-Releasing Peptide (ProGRP): Considered more specific for SCLC than NSE, ProGRP is elevated in the majority of patients with SCLC. It is particularly useful in distinguishing SCLC from non-small cell lung cancer (NSCLC) and in monitoring disease recurrence or progression. ProGRP has emerged as the most promising serum marker for SCLC, but its routine use is not yet universally adopted.
• Chromogranin A: Frequently elevated in SCLC, but less specific and less sensitive than NSE or ProGRP. Its main role is as a general neuroendocrine marker.
• Other Markers: Lactate dehydrogenase (LDH) and cytokeratin fragments (CYFRA 21-1) may be elevated but are non-specific.

Table 4: Common Tumor Markers in SCLC

Despite their limitations, tumor markers can be useful for baseline assessment and monitoring treatment response, especially when imaging findings are equivocal or when repeated imaging is not feasible. Serial measurement of NSE or ProGRP may help detect relapse earlier, although this should always be confirmed with imaging and clinical evaluation.

G) Value of Diagnostic Methods (Imaging) in SCLC

Imaging plays a central role in the diagnosis, staging, and follow-up of SCLC. Given the aggressive nature of the disease and its tendency for early dissemination, accurate and timely imaging is critical for optimal management.

Key Imaging Modalities:

• Chest and Upper Abdomen CT Scan: The initial imaging modality of choice for suspected lung cancer. CT provides detailed information on the size, location, and extent of the primary tumor, as well as involvement of mediastinal lymph nodes and detection of liver and adrenal metastases.
• Positron Emission Tomography–Computed Tomography (PET-CT): ): PET-CT with 18F-FDG is increasingly used for staging, as it improves detection of extrathoracic metastases and can upstage a significant proportion of patients initially thought to have limited-stage disease. However, PET-CT is less sensitive for detecting brain metastases and may not be available in all settings.
• Magnetic Resonance Imaging (MRI) of the Brain: Given the high risk of CNS involvement in SCLC, brain MRI is recommended at diagnosis for all patients, regardless of neurological symptoms. MRI is superior to CT for detecting small or asymptomatic brain metastases, which can alter staging and management.
• Bone Scan: Previously standard for detecting bone metastases, but now largely supplanted by PET-CT, which offers greater sensitivity and specificity.

Table 5. Imaging Modalities in SCLC Diagnosis and Staging

Imaging in Follow-up and Response Assessment

During and after treatment, imaging is essential for evaluating response, detecting relapse, and guiding further management. CT scans are typically performed every 2–3 cycles during therapy and at regular intervals in follow-up. PET-CT may be useful in select cases, particularly when recurrence is suspected but not confirmed by conventional imaging.(Photos 1; 2; 3. Courtesy of Dr. Adrián Hunis)

Photo 1: Images pretreatment

Photos 2 and 3: Images through the first three months post platinum-based chemotherapy

"Important decrease in size of the primary-looking lesion described around the right lower lobar bronchus, as well as adenopathies evidenced in the mediastinum and documented secondary lesions in bone, liver and pleura. These injuries currently do not show pathological accumulation of the radio drug.

The bilateral pulmonary nodular images have also decreased in size, being almost imperceptible in the present study.

Decreased metabolic activity of the focus described in the breast the surgical changes of the sternotomy"

H) Emerging Techniques

Recent advances include the use of radiomics and artificial intelligence to analyze imaging data, potentially improving diagnostic accuracy and prognostication. Additionally, the integration of liquid biopsy with imaging is under investigation for early detection of relapse and minimal residual disease.

I) Summary

While tumor markers provide useful adjunctive information, imaging remains the gold standard for diagnosis, staging, and monitoring in SCLC. The combination of advanced imaging modalities and judicious use of serum markers enhances the accuracy of diagnosis and the effectiveness of treatment strategies in this aggressive disease.

J) Treatments

J1. Surgery

Surgical resection is rarely indicated in SCLC, given the high likelihood of early dissemination. However, for the small subset of patients with very limited-stage disease (T1-2N0), surgery followed by adjuvant chemotherapy can be considered. Retrospective studies suggest that selected patients may benefit from this approach, but randomized data are limited. Multidisciplinary evaluation is essential to identify appropriate candidates for surgery.

J2. Radiotherapy

Radiotherapy is a cornerstone of SCLC treatment, particularly for limited-stage disease. The standard approach is concurrent chemoradiotherapy, with thoracic irradiation delivered either once or twice daily. The landmark Turrisi trial demonstrated a survival benefit for twice-daily radiotherapy, though this regimen is more intensive and may not be feasible for all patients.

Advances in radiotherapy techniques, such as intensity-modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT), have improved local control and reduced toxicity. Prophylactic cranial irradiation (PCI) is also recommended for patients with limited-stage SCLC who achieve a complete response, as it reduces the risk of brain metastases and improves survival.

J3. Medical Treatment

Chemotherapy

For decades, the backbone of SCLC treatment has been platinum-based chemotherapy, typically etoposide with cisplatin or carboplatin. Initial response rates are high—60–80% in extensive-stage disease—but relapse is almost universal, and median overall survival remains poor. Topotecan is the only approved second-line agent, with modest activity. (Fig. 3)

Figure 3. Kaplan-Meier Curve: Overall Survival in Extensive-Stage SCLC (2010–2020)

Tyrosine Kinase Inhibitors (TKIs)

Unlike NSCLC, actionable driver mutations are rare in SCLC. However, ongoing trials are evaluating TKIs targeting c-MET, FGFR1, and DLL3, among others. Thus far, results have been disappointing, but research continues, particularly in molecularly defined subgroups.

Antibody-Drug Conjugates (ADC) & Monoclonal Antibodies (MC)

Rovalpituzumab tesirine, an anti-DLL3 antibody-drug conjugate, showed initial promise in early-phase trials but was discontinued due to toxicity and lack of survival benefit in phase III studies. Other ADCs and monoclonal antibodies are in development, targeting novel antigens identified through molecular profiling.

Immunotherapy

The most significant advance in SCLC over the last decade has been the introduction of immunotherapy.

The IMpower133 and CASPIAN trials demonstrated that adding the immune checkpoint inhibitors atezolizumab or durvalumab to first-line chemotherapy significantly improves overall survival in extensive-stage SCLC. These results have established chemoimmunotherapy as the new standard of care in this setting.

Despite these advances, the absolute survival benefit remains modest, and most patients relapse within a year. Efforts are ongoing to identify biomarkers of response and to develop combination regimens that may further improve outcomes.

Novel Agents and Ongoing Protocols

Lurbinectedin, a novel transcription inhibitor, has demonstrated activity in relapsed SCLC and is now approved in some regions. Other agents under investigation include PARP inhibitors, bispecific T-cell engagers, and epigenetic modulators. Numerous clinical trials are ongoing, reflecting the high unmet need in this disease.

K) Management of CNS Metastases

SCLC has a high propensity for brain metastases, with up to 50% of patients developing CNS involvement during their disease course. Prophylactic cranial irradiation (PCI) has been shown to reduce the incidence of brain metastases and improve survival in limited-stage SCLC. However, its role in extensive-stage disease is more controversial, as recent studies have raised concerns about neurotoxicity and questioned the survival benefit in the era of modern imaging and systemic therapy.

MRI surveillance is increasingly being considered as an alternative to PCI in selected patients, particularly those who achieve a good response to systemic therapy and are at higher risk of cognitive decline.

In 2023, ASCO published a guideline on systemic therapy for small cell lung cancer (SCLC). The recently published results of the phase III ADRIATIC trial and the phase II DeLLphi-301 trial have prompted this amendment to the guideline.

Methods

A targeted electronic literature search to identify clinical trials in this patient population was conducted and one phase III randomized control trial and one phase II clinical trial were found. The original guideline Expert Panel was reconvened to review new evidence from the phase III

ADRIATIC trial and the phase II DeLLphi-301 trial, and to review and approve the revised recommendations.

SYSTEMIC THERAPY FOR SCLC ALGORITHM (ASCO)

SYSTEMIC THERAPY FOR RELAPSED SCLC ALGORITHM (ASCO)

L) Current Status

Despite significant advances, SCLC remains a formidable clinical challenge. The integration of immunotherapy into first-line treatment has modestly improved survival, and molecular subtyping offers hope for more personalized approaches. However, the majority of patients still experience relapse, and five-year survival rates remain below 7% for extensive-stage disease. The need for novel therapies and better biomarkers is urgent.

M) Future Perspectives

Looking ahead, several avenues hold promise for improving outcomes in SCLC. Liquid biopsies may enable real-time monitoring of disease and resistance mechanisms, facilitating more adaptive treatment strategies. Novel immunotherapies, such as bispecific antibodies and CAR-T cells, are in early-phase trials and may offer new hope for patients with relapsed or refractory disease. A deeper understanding of tumor heterogeneity and the tumor microenvironment will be essential to overcoming therapeutic resistance and developing more effective, personalized therapies.

N) Conclusions

The last decade has brought significant, if incremental, progress in SCLC, particularly with the advent of immunotherapy and molecular subtyping. While survival gains remain modest, the field is rapidly evolving, and ongoing research offers hope for more effective, personalized therapies in the near future. Continued collaboration between clinicians, researchers, and patients will be essential to translating these advances into improved outcomes for all patients with SCLC.